Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred StockGlobeNewsWire • 09/22/20
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred StockGlobeNewsWire • 09/21/20
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease IndicationsGlobeNewsWire • 09/08/20
